Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%

INTRODUCTION: The optimal first-line immunotherapy regimen for advanced non-squamous non-small cell lung cancer (NS-NSCLC) patients with programmed cell death ligand 1 (PD-L1) expression ≥ 50% remains unclear. Our aim is to determine the most effective treatment regimen through a network meta-analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wei, Chen, Jiayi, Zhang, Lin, Cheng, Sheng, Yu, Junxian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464425/
https://www.ncbi.nlm.nih.gov/pubmed/37612622
http://dx.doi.org/10.1186/s12885-023-11285-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464425/
https://www.ncbi.nlm.nih.gov/pubmed/37612622
http://dx.doi.org/10.1186/s12885-023-11285-4

Ejemplares similares